Provost Jean-Claude 4
4 · Lantheus Holdings, Inc. · Filed Mar 6, 2023
Insider Transaction Report
Form 4
Provost Jean-Claude
Chief Medical Officer
Transactions
- Award
Stock Option (right to buy)
2023-03-02+9,535→ 9,535 total(indirect: By Theranostics Consulting SAS)Exercise: $73.35Exp: 2033-03-02→ Common Stock (9,535 underlying) - Award
Common Stock
2023-03-02+16,359→ 20,823 total(indirect: By Theranostics Consulting SAS)
Footnotes (3)
- [F1]Consists of 5,453 restricted stock units that vest in equal installments over a three-year period and 10,906 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
- [F2]The reporting person is the managing partner of the company that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F3]The option vests in three equal annual installments beginning on March 2, 2024.